Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

Current hematologic malignancy reports - 1 Sept 2015

Roberts Daniel A, Steensma David P

Abstract excerpt

The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 % of patients experience complete hematologic and cytogenetic response. Moreover, once an HMA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to DNA Modification Methylases

Share to Drug Substitution

Share to Epigenesis, Genetic

Share to Myelodysplastic Syndromes

Share to Treatment Failure

Source

Identifiers

PMID: 26126600
DOI: 10.1007/s11899-015-0273-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.PMID 26126600Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating AgentsSemantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.